Children carrying KMT2Ar present with distinct clinical and molecular features, including monocytic differentiation, higher WCC, higher expression of CD33, fewer co-occurring mutations compared with KMT2A wild-type AML, and higher expression of HOXA/MEIS1 genes. The gene discussed is CD33; the disease is acute myeloid leukemia.